Myocardial Infarction Drug Market Report

Global and Region Myocardial Infarction Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：150
  • REPORT CODE：GMM1013153
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Myocardial Infarction Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Myocardial Infarction Drugmarket, defines the market attractiveness level of Myocardial Infarction Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Myocardial Infarction Drug industry, describes the types of Myocardial Infarction Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Myocardial Infarction Drug market and the development prospects and opportunities of Myocardial Infarction Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Myocardial Infarction Drug market in Chapter 13.

    By Player:

    • Compugen Ltd

    • Cynata Therapeutics Limited

    • CellProthera

    • Capricor Therapeutics, Inc

    • CSL Limited

    • Lee's Pharmaceutical Holdings Limited

    • LegoChem Biosciences, Inc

    • Juventas Therapeutics, Inc

    • HUYA Bioscience International, LLC

    • Human Stem Cells Institute

    • Immune Pharmaceuticals Inc

    • Hemostemix Ltd

    • BioCardia, Inc

    • FibroGen, Inc

    • Celyad SA

    • Laboratoires Pierre Fabre SA

    • Biscayne Pharmaceuticals, Inc

    By Type:

    • JVS-200

    • KR-33028

    • AMRS-001

    • ANG-4011

    • Balixafortide

    • CAP-1002

    • Cenderitide

    • Others

    By End-User:

    • Research Center

    • Hospital

    • Clinic

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Myocardial Infarction Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Myocardial Infarction Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Myocardial Infarction Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Myocardial Infarction Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Myocardial Infarction Drug Market Analysis and Outlook to 2022

    • 7.1 Global Myocardial Infarction Drug Consumption (2017-2022)

    • 7.2 United States Myocardial Infarction Drug Consumption (2017-2022)

    • 7.3 Europe Myocardial Infarction Drug Consumption (2017-2022)

    • 7.4 China Myocardial Infarction Drug Consumption (2017-2022)

    • 7.5 Japan Myocardial Infarction Drug Consumption (2017-2022)

    • 7.6 India Myocardial Infarction Drug Consumption (2017-2022)

    • 7.7 South Korea Myocardial Infarction Drug Consumption (2017-2022)

    8 Region and Country-wise Myocardial Infarction Drug Market Analysis and Outlook to 2028

    • 8.1 Global Myocardial Infarction Drug Consumption Forecast (2022-2028)

    • 8.2 United States Myocardial Infarction Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Myocardial Infarction Drug Consumption Forecast (2022-2028)

    • 8.4 China Myocardial Infarction Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Myocardial Infarction Drug Consumption Forecast (2022-2028)

    • 8.6 India Myocardial Infarction Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Myocardial Infarction Drug Consumption Forecast (2022-2028)

    9 Global Myocardial Infarction Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Myocardial Infarction Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global JVS-200 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global KR-33028 Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global AMRS-001 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global ANG-4011 Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Balixafortide Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global CAP-1002 Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Cenderitide Consumption and Growth Rate (2017-2022)

      • 9.1.8 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Myocardial Infarction Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Research Center Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Clinic Consumption and Growth Rate (2017-2022)

    10 Global Myocardial Infarction Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Myocardial Infarction Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global JVS-200 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global KR-33028 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global AMRS-001 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global ANG-4011 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Balixafortide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global CAP-1002 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.7 Global Cenderitide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.8 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Myocardial Infarction Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Research Center Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    11 Global Myocardial Infarction Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Myocardial Infarction Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Myocardial Infarction Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Myocardial Infarction Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Myocardial Infarction Drug Market Competitive Analysis

    • 14.1 Compugen Ltd

      • 14.1.1 Compugen Ltd Company Details

      • 14.1.2 Compugen Ltd Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Compugen Ltd Myocardial Infarction Drug Product and Service

    • 14.2 Cynata Therapeutics Limited

      • 14.2.1 Cynata Therapeutics Limited Company Details

      • 14.2.2 Cynata Therapeutics Limited Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Cynata Therapeutics Limited Myocardial Infarction Drug Product and Service

    • 14.3 CellProthera

      • 14.3.1 CellProthera Company Details

      • 14.3.2 CellProthera Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 CellProthera Myocardial Infarction Drug Product and Service

    • 14.4 Capricor Therapeutics, Inc

      • 14.4.1 Capricor Therapeutics, Inc Company Details

      • 14.4.2 Capricor Therapeutics, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Capricor Therapeutics, Inc Myocardial Infarction Drug Product and Service

    • 14.5 CSL Limited

      • 14.5.1 CSL Limited Company Details

      • 14.5.2 CSL Limited Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 CSL Limited Myocardial Infarction Drug Product and Service

    • 14.6 Lee's Pharmaceutical Holdings Limited

      • 14.6.1 Lee's Pharmaceutical Holdings Limited Company Details

      • 14.6.2 Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Product and Service

    • 14.7 LegoChem Biosciences, Inc

      • 14.7.1 LegoChem Biosciences, Inc Company Details

      • 14.7.2 LegoChem Biosciences, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 LegoChem Biosciences, Inc Myocardial Infarction Drug Product and Service

    • 14.8 Juventas Therapeutics, Inc

      • 14.8.1 Juventas Therapeutics, Inc Company Details

      • 14.8.2 Juventas Therapeutics, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Juventas Therapeutics, Inc Myocardial Infarction Drug Product and Service

    • 14.9 HUYA Bioscience International, LLC

      • 14.9.1 HUYA Bioscience International, LLC Company Details

      • 14.9.2 HUYA Bioscience International, LLC Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 HUYA Bioscience International, LLC Myocardial Infarction Drug Product and Service

    • 14.10 Human Stem Cells Institute

      • 14.10.1 Human Stem Cells Institute Company Details

      • 14.10.2 Human Stem Cells Institute Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Human Stem Cells Institute Myocardial Infarction Drug Product and Service

    • 14.11 Immune Pharmaceuticals Inc

      • 14.11.1 Immune Pharmaceuticals Inc Company Details

      • 14.11.2 Immune Pharmaceuticals Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Immune Pharmaceuticals Inc Myocardial Infarction Drug Product and Service

    • 14.12 Hemostemix Ltd

      • 14.12.1 Hemostemix Ltd Company Details

      • 14.12.2 Hemostemix Ltd Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Hemostemix Ltd Myocardial Infarction Drug Product and Service

    • 14.13 BioCardia, Inc

      • 14.13.1 BioCardia, Inc Company Details

      • 14.13.2 BioCardia, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 BioCardia, Inc Myocardial Infarction Drug Product and Service

    • 14.14 FibroGen, Inc

      • 14.14.1 FibroGen, Inc Company Details

      • 14.14.2 FibroGen, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 FibroGen, Inc Myocardial Infarction Drug Product and Service

    • 14.15 Celyad SA

      • 14.15.1 Celyad SA Company Details

      • 14.15.2 Celyad SA Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Celyad SA Myocardial Infarction Drug Product and Service

    • 14.16 Laboratoires Pierre Fabre SA

      • 14.16.1 Laboratoires Pierre Fabre SA Company Details

      • 14.16.2 Laboratoires Pierre Fabre SA Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Laboratoires Pierre Fabre SA Myocardial Infarction Drug Product and Service

    • 14.17 Biscayne Pharmaceuticals, Inc

      • 14.17.1 Biscayne Pharmaceuticals, Inc Company Details

      • 14.17.2 Biscayne Pharmaceuticals, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Biscayne Pharmaceuticals, Inc Myocardial Infarction Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Myocardial Infarction Drug

    • Figure Myocardial Infarction Drug Picture

    • Table Global Myocardial Infarction Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Myocardial Infarction Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Myocardial Infarction Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Myocardial Infarction Drug Consumption by Country (2017-2022)

    • Figure United States Myocardial Infarction Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Myocardial Infarction Drug Consumption and Growth Rate (2017-2022)

    • Figure China Myocardial Infarction Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Myocardial Infarction Drug Consumption and Growth Rate (2017-2022)

    • Figure India Myocardial Infarction Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Myocardial Infarction Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Myocardial Infarction Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Myocardial Infarction Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Myocardial Infarction Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Myocardial Infarction Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Myocardial Infarction Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Myocardial Infarction Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Myocardial Infarction Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global JVS-200 Consumption and Growth Rate (2017-2022)

    • Figure Global KR-33028 Consumption and Growth Rate (2017-2022)

    • Figure Global AMRS-001 Consumption and Growth Rate (2017-2022)

    • Figure Global ANG-4011 Consumption and Growth Rate (2017-2022)

    • Figure Global Balixafortide Consumption and Growth Rate (2017-2022)

    • Figure Global CAP-1002 Consumption and Growth Rate (2017-2022)

    • Figure Global Cenderitide Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Research Center Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global JVS-200 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global KR-33028 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global AMRS-001 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ANG-4011 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Balixafortide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CAP-1002 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cenderitide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Research Center Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Myocardial Infarction Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Myocardial Infarction Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table Compugen Ltd (Foundation Year, Company Profile and etc.)

    • Table Compugen Ltd Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Compugen Ltd Myocardial Infarction Drug Product and Service

    • Table Cynata Therapeutics Limited (Foundation Year, Company Profile and etc.)

    • Table Cynata Therapeutics Limited Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cynata Therapeutics Limited Myocardial Infarction Drug Product and Service

    • Table CellProthera (Foundation Year, Company Profile and etc.)

    • Table CellProthera Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table CellProthera Myocardial Infarction Drug Product and Service

    • Table Capricor Therapeutics, Inc (Foundation Year, Company Profile and etc.)

    • Table Capricor Therapeutics, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Capricor Therapeutics, Inc Myocardial Infarction Drug Product and Service

    • Table CSL Limited (Foundation Year, Company Profile and etc.)

    • Table CSL Limited Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSL Limited Myocardial Infarction Drug Product and Service

    • Table Lee's Pharmaceutical Holdings Limited (Foundation Year, Company Profile and etc.)

    • Table Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Product and Service

    • Table LegoChem Biosciences, Inc (Foundation Year, Company Profile and etc.)

    • Table LegoChem Biosciences, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table LegoChem Biosciences, Inc Myocardial Infarction Drug Product and Service

    • Table Juventas Therapeutics, Inc (Foundation Year, Company Profile and etc.)

    • Table Juventas Therapeutics, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Juventas Therapeutics, Inc Myocardial Infarction Drug Product and Service

    • Table HUYA Bioscience International, LLC (Foundation Year, Company Profile and etc.)

    • Table HUYA Bioscience International, LLC Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table HUYA Bioscience International, LLC Myocardial Infarction Drug Product and Service

    • Table Human Stem Cells Institute (Foundation Year, Company Profile and etc.)

    • Table Human Stem Cells Institute Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Human Stem Cells Institute Myocardial Infarction Drug Product and Service

    • Table Immune Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Immune Pharmaceuticals Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immune Pharmaceuticals Inc Myocardial Infarction Drug Product and Service

    • Table Hemostemix Ltd (Foundation Year, Company Profile and etc.)

    • Table Hemostemix Ltd Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hemostemix Ltd Myocardial Infarction Drug Product and Service

    • Table BioCardia, Inc (Foundation Year, Company Profile and etc.)

    • Table BioCardia, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioCardia, Inc Myocardial Infarction Drug Product and Service

    • Table FibroGen, Inc (Foundation Year, Company Profile and etc.)

    • Table FibroGen, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table FibroGen, Inc Myocardial Infarction Drug Product and Service

    • Table Celyad SA (Foundation Year, Company Profile and etc.)

    • Table Celyad SA Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celyad SA Myocardial Infarction Drug Product and Service

    • Table Laboratoires Pierre Fabre SA (Foundation Year, Company Profile and etc.)

    • Table Laboratoires Pierre Fabre SA Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Laboratoires Pierre Fabre SA Myocardial Infarction Drug Product and Service

    • Table Biscayne Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)

    • Table Biscayne Pharmaceuticals, Inc Myocardial Infarction Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biscayne Pharmaceuticals, Inc Myocardial Infarction Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US